CVS to Split Into Two Public Companies, Tax-Free, by First Half of 2028
CVS sits 32% above its 52-week low of $69.51 on elevated volume (2.4× avg).
Summary
CVS plans to separate into two independent public companies — a healthcare solutions business and CVS Pharmacy — in a transaction intended to be tax-free to shareholders, targeted for completion in the first half of 2028.
Key Events · M&A and Partnerships · CVS
-
CVS Announces Two-Company Separation
Board-approved plan to split into a healthcare solutions company (Aetna, CVS Caremark, CVS Specialty, Oak Street Health, Signify Health) and CVS Pharmacy (approximately 9,000 pharmacies, mail pharmacy, MinuteClinic, Health100).
-
Tax-Free Structure, 1H 2028 Target
Separation is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes, with completion expected in the first half of 2028.
-
Leadership Named for Both Companies
David Joyner, currently Chairman and CEO of CVS Health, will chair and run the healthcare solutions company; Prem Shah, currently Group President, will be CEO of CVS Pharmacy.
-
Conditions Still Outstanding
Completion is subject to final board approval, effectiveness of a Form 10 registration statement with the SEC, and receipt of customary confirmation of tax-free treatment; additional leaders and board members will be announced later.
Analysis · CVS · Trade & Services
CVS is breaking itself in two: a healthcare solutions company (Aetna, Caremark, Specialty, Oak Street, Signify) and CVS Pharmacy (about 9,000 stores, MinuteClinic, Health100). The split is intended to be tax-free to shareholders, with both companies expected to carry solid investment grade ratings and pay attractive dividends. For a $117 billion company, this is a thesis-altering event — it changes what investors own, how each business is valued, and who runs each piece (Joyner at the solutions company, Shah at the pharmacy company). The long runway matters: completion is targeted for the first half of 2028, subject to board final approval, an effective Form 10 registration, and tax-free confirmation, so the structure can still change. It follows press reports of spin-off talks on 2026-11-03 and lands the same morning as Q3 results and raised guidance, which gives management a stronger hand going into the separation.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVS was trading at $91.86 on NYSE in the Trade & Services sector, with a market capitalization of approximately $116.9B. The 52-week trading range was $69.51 to $110.68. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.